Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Minerva Pediatr ; 67(3): 269-74, 2015 Jun.
Article in Italian | MEDLINE | ID: mdl-25941133

ABSTRACT

The relation of infectious agents to arthritis is an area of great interest to the rheumatologist. Septic arthritis of bacterial origin accounts for approximately 6.5% of all childhood arthritides. Septic arthritis usually results from haematogenous spread from a focus of infection elsewhere in the body, but also by direct extension of an infection from overlying soft tissues or bone or traumatic invasion of the joint. As a result, if a focus of underlying osteomyelitis breaks throught the metaphysis, it may enter the joint and result in septic arthritis. Systemic signs of illness are fever, severe bone pain, and tenderness with or without local swelling. A wide range of microorganism can cause septic arthritis in children; Staphylococcus aureus and nongroup A and B streptococci are most common overall. However, different organisms are more common at some ages and in certain circumstances. Kingella kingae is an emerging pathogen in young children under 4 years of age. The clinical presentation of K. kingae invasive infection is often subtle and may be associated to mild to moderate biologic inflammatory responses. Affected children often have few signs and symptoms of osteoarticular infections. Early MRI is useful in differentiating K kingae from Gram-positive cocci in osteoarticular infections. Cartilaginous involvement, modest soft tissue and bone reaction suggest K. kingae. It's very important to include K. kingae in differential diagnosis of osteoarticular infections in young children. We report an unusual case of osteomyelitis: clinical manifestations and MRI are suggestive for K kingae infection.


Subject(s)
Kingella kingae/isolation & purification , Neisseriaceae Infections/diagnosis , Osteomyelitis/diagnosis , Child, Preschool , Diagnosis, Differential , Female , Humans , Magnetic Resonance Imaging , Neisseriaceae Infections/microbiology , Osteomyelitis/microbiology , Osteomyelitis/physiopathology
2.
Dig Liver Dis ; 39(11): 1018-23, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17652044

ABSTRACT

BACKGROUND: Glycogen storage diseases are inherited defects which cause accumulation of glycogen in the tissues. Hepatic steatosis is defined as accumulation of fat within hepatocytes. On sonography, liver shows increased echogenicity both in glycogen storage diseases and steatosis. Liver hyperechogenicity in glycogen storage diseases may depend on accumulation of glycogen and/or fat. Chemical-shift magnetic resonance imaging can discriminate tissues only containing water from those containing both fat and water. AIM: The primary aim of the present study was to evaluate the usefulness of liver chemical-shift magnetic resonance imaging for detecting liver steatosis in patients with metabolic impairment due to glycogen storage diseases. SUBJECTS: Twelve patients with type I (n=8) or type III (n=4) glycogen storage diseases were studied and compared to 12 obese-overweight subjects with known liver steatosis. As control group 12 lean normal voluntary subjects were recruited. METHODS: Liver was evaluated by sonography and chemical-shift magnetic resonance imaging to calculate hepatic fat fraction. RESULTS: A significant difference in echogenicity between patients with glycogen storage diseases and normal subjects was observed (p<0.05), while this difference was not present between overweight-obese and glycogen storage diseases patients. On the contrary, fat fraction was similar between glycogen storage diseases patients and normal subjects and different between glycogen storage diseases patients and overweight-obese (p<0.05). CONCLUSION: The present data suggest that chemical-shift magnetic resonance imaging may exclude fat deposition as a cause of liver hyperechogenicity in subjects with glycogen storage diseases.


Subject(s)
Fatty Liver/complications , Fatty Liver/diagnosis , Glycogen Storage Disease/complications , Magnetic Resonance Imaging , Adolescent , Adult , Child , Fatty Liver/diagnostic imaging , Female , Glycogen Storage Disease/metabolism , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Obesity/complications , Ultrasonography
3.
Clin Endocrinol (Oxf) ; 63(1): 19-25, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15963056

ABSTRACT

BACKGROUND: The efficacy of ACE-inhibitors in decreasing microalbuminuria and proteinuria has been reported in a few patients with glycogen storage disease type 1 (GSD1); however, no case-control study has ever been published. AIM: The aim of the current study was to evaluate the efficacy of ACE-inhibitors in reducing glomerular hyperfiltration, microalbuminuria and proteinuria, and in delaying the progression of renal damage. PATIENTS AND METHODS: Ninety-five patients (median age at the time of the study: 14.5 years) were enrolled from nine Italian referral centres for metabolic diseases. A retrospective study of a 10-year follow-up was conducted in order to compare the evolution of these parameters in treated patients with those who were not treated with ACE-inhibitors. RESULTS: A significant and progressive decrease of glomerular filtration rate was observed in treated patients vs. those who were not treated with ACE-inhibitors (P < 0.05). No difference was observed for microalbuminuria and proteinuria between the two groups of patients. Moreover, the ACE-inhibitors significantly delayed the progression from glomerular hyperfiltration to microalbuminuria, but not that from microalbuminuria to proteinuria. CONCLUSIONS: The results of the present study underline the importance of a strict follow-up of renal function in GSD1 patients. The detection of glomerular hyperfiltration suggests precocious initiation of ACE-inhibitor treatment to delay the progression of renal damage. A randomized prospective study is needed to establish for certain the real effectiveness of this treatment in GSD1 patients.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Glycogen Storage Disease Type I/complications , Kidney Diseases/prevention & control , Adolescent , Adult , Age of Onset , Albuminuria/physiopathology , Albuminuria/prevention & control , Child , Child, Preschool , Disease Progression , Glomerular Filtration Rate/drug effects , Glycogen Storage Disease Type I/physiopathology , Humans , Infant , Kidney Diseases/etiology , Kidney Diseases/physiopathology , Proteinuria/physiopathology , Proteinuria/prevention & control , Retrospective Studies , Severity of Illness Index , Treatment Outcome
4.
Pediatr Med Chir ; 26(1): 50-2, 2004.
Article in English | MEDLINE | ID: mdl-15529812

ABSTRACT

HCV vertically acquired infection is asymptomatic and characterized by a high chronic infection rate; only 9% of HCV infected children shows spontaneous remission. As far as a mild course of the disease has been observed during childhood, we hypothesize that any eventual treatment intervention could be postpone until adolescent age.


Subject(s)
Hepatitis C/transmission , Infectious Disease Transmission, Vertical , Female , Follow-Up Studies , Humans , Infant, Newborn , Longitudinal Studies , Male , Prospective Studies , Time Factors
5.
Pediatr Med Chir ; 25(1): 6-11, 2003.
Article in English | MEDLINE | ID: mdl-12920971

ABSTRACT

Mother-to-child transmission of hepatitis C virus can take place in utero, during labour or after birth. Rate of vertical transmission varies widely between surveys but is around 5-6%. Maternal risk factors which may condition perinatal transmission risk are HIV/HCV coinfection, drug use, viral load, viral genotype, type of delivery and breastfeeding. On the basis of recent data, we propose a step-wise follow-up for HCV seropositive mothers and their infants. This proposal might represent an important occasion to unify behaviors in different Obstetrics-Gynecology and Neonatology Units.


Subject(s)
Health Planning Guidelines , Hepatitis C/transmission , Adult , Antibodies, Viral , Breast Feeding , Delivery, Obstetric , Enzyme-Linked Immunosorbent Assay , Female , Genotype , Health Services/supply & distribution , Hepatitis C/immunology , Humans , Infant, Newborn , Infectious Disease Transmission, Vertical , Polymerase Chain Reaction
6.
Minerva Pediatr ; 55(2): 149-55, 2003 Apr.
Article in Italian | MEDLINE | ID: mdl-12754459

ABSTRACT

BACKGROUND: Epidemiologic data suggest strong links between hospitalisation with bronchiolitis in infancy and subsequent higher risk of developing lower respiratory tract infections (LRTI) and/or hyperreactive airway diseases. The aim of this study was to evaluate in an Italian population the natural history of respiratory diseases in children hospitalised for LRTI when they were <2 years. METHODS: An observational, perspective, longitudinal study was performed through telephone interviews. Nine pediatric tertiary care centres participated to the study evaluating a population of 187 children, hospitalised in the previous year (November 1999-April 2000) for bronchiolitis or pneumonia when they were <2 years of age and participated to a previous study on the prevalence of infant LRTI in Italy (RADAR). RESULTS: Twenty-three (12.3%) children had a gestational age <36 weeks. In the 12 months following the first hospitalisation, an elevated frequency of respiratory symptoms was found. Indeed, 152 (81.3%) children suffered from not-requiring-hospital-admission respiratory infections and 21 (11.2%) were hospitalized again for LRTI: 11.6% had bronchiolitis, 23.5% bronchitis and 35.2% pneumonia. In addition, 1.2% had gs;3 infectious episodes and 21.4% gs;6: 68 (36.4%) showed wheezy bronchitis and 17 (9.1%) were reported to have asthma; 132 children (71%) took antibiotics during the last year, 19.4% >3 times; 111 (59.4%) bronchodilators and 49 (26.2%) oral corticosteroids. One year after the first hospitalisation, 19 subjects (10.2%) were found to be positive to at least one class of allergens by prick test or RAST. CONCLUSIONS: Thus, the demonstration of a high morbidity rate for LRTI, wheezing and asthma in this study group during the first year follow-up after hospital admission further support the need for prophylactic interventions to reduce the morbidity and severity of sequelae of LRTI, in particularly in premature children and/or with additional risk factors.


Subject(s)
Asthma/epidemiology , Bronchitis/epidemiology , Pneumonia, Viral/epidemiology , Anti-Bacterial Agents/therapeutic use , Bronchitis/virology , Female , Follow-Up Studies , Hospitalization/statistics & numerical data , Humans , Hypersensitivity, Immediate/epidemiology , Infant , Infant, Newborn , Infant, Premature , Italy/epidemiology , Longitudinal Studies , Male , Prospective Studies , Respiratory Sounds , Respiratory System Agents/therapeutic use , Risk Factors , Virus Diseases/epidemiology
7.
J Int Med Res ; 29(4): 349-54, 2001.
Article in English | MEDLINE | ID: mdl-11675909

ABSTRACT

The aim of this study was to evaluate the efficacy of cefaclor in the prophylaxis of recurrent acute otitis media (AOM) in human immunodeficiency virus (HIV)-infected children. The study was carried out in children born between 1 January 1986 and 31 December 1996 who had been vertically HIV infected Patients who had experienced recurrent AOM between October 1997 and March 1998 (period 1) were eligible for the trial. Recurrent AOM was defined as the occurrence in the same patient of three or more episodes of AOM within 6 months of the observation period. Patients recruited for this trial received cefaclor at a dose of 20 mg/kg once daily for 6 months between April and September 1998 (period 2). Clinical observation was carried out in periods 1 and 2 and for the first 6 months after prophylaxis, i.e. October 1998 - March 1999 (period 3). Natural killer-cell activity, phagocytosis and myeloperoxidase activity were determined before and at the end of the prophylactic period. For each period, CD4-cell count measurement and CD4-positive cell class were recorded. Seventeen children were recruited for this trial. No significant differences were observed in natural killer-cell activity between periods 1 and 2, nor were any significant differences observed in CD4-positive cell class or CD4-positive cell count between the three periods. However, cefaclor administration was associated with a reduction in the number of AOM episodes in 100% of cases and a mean increase in myeloperoxidase activity in 57% of cases. This suggests that cefaclor may be useful in the prophylaxis of recurrent AOM in HIV-infected children.


Subject(s)
Cefaclor/pharmacology , Cephalosporins/pharmacology , HIV Infections/complications , Otitis Media/complications , Otitis Media/prevention & control , Acute Disease , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Cefaclor/administration & dosage , Cefaclor/adverse effects , Cephalosporins/administration & dosage , Cephalosporins/adverse effects , Child , Child, Preschool , Female , HIV Infections/drug therapy , HIV Infections/immunology , HIV Infections/transmission , Humans , Infectious Disease Transmission, Vertical , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Longitudinal Studies , Male , Otitis Media/immunology , Peroxidase/blood , Phagocytosis/drug effects , Recurrence
8.
Pediatrics ; 106(5): E73, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11061810

ABSTRACT

OBJECTIVE: The growth of infants with atopic dermatitis (AD) has been poorly investigated based on the early type of feeding. The aim of this study was to assess the growth pattern of AD infants during the first 12 months of life in comparison to healthy infants, according to the early type of feeding (breastfed or nonbreastfed). METHODS: Fifty-five term AD infants (36 breastfed and 19 nonbreastfed) and 114 term healthy infants (58 breastfed and 56 nonbreastfed) were evaluated by standardized growth indices (z scores; National Center for Health Statistics-World Health Organization data) through the first 12 months of life. RESULTS: No difference was found between AD and healthy groups at birth. In AD infants, weight (WA) and length (LA) z scores decreased with age and were significantly lower, compared with healthy infants from the second month of age onward. The difference of mean z scores between AD and healthy infants at 12 months of age was -.69 (95% confidence interval [CI]: -1.00 to -.38) for WA and -.67 (95% CI: -.98 to -.36) for LA. The growth pattern of AD infants was not influenced by the early type of feeding, whereas in the 6- to 12-month period, the delay in growth was more pronounced in patients with more severe dermatitis. CONCLUSIONS: In the first year of life, AD infants show a progressive impairment in growth irrespective of the early type of feeding. The severity of disease may be an independent factor negatively influencing growth.


Subject(s)
Bottle Feeding/statistics & numerical data , Breast Feeding , Child Development/physiology , Dermatitis, Atopic/physiopathology , Growth Disorders/physiopathology , Infant Food , Infant Nutritional Physiological Phenomena/physiology , Age Factors , Dermatitis, Atopic/diagnosis , Female , Food Hypersensitivity/diagnosis , Food Hypersensitivity/physiopathology , Gestational Age , Growth/physiology , Growth Disorders/diagnosis , Humans , Infant , Infant Food/adverse effects , Infant, Newborn , Male , Severity of Illness Index
9.
Arch Dis Child ; 81(5): 395-9, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10519710

ABSTRACT

AIM: To compare the growth patterns of breast fed and formula fed Italian infants in the first 12 months of life using World Health Organisation (WHO) reference data. METHODS: The growth patterns of 73 breast fed infants (36 male, 37 female) and 65 formula fed infants (35 male, 30 female) were compared. Solid foods were introduced with the same weaning schedules from the 5th month in both groups. The weight for age (WA), length for age (LA), and weight for length (WL) z scores (National Center for Health Statistics-WHO data) were calculated at birth, 1, 2, 3, 4, 6, 9, and 12 months. RESULTS: Breast fed infants had the highest z scores (WA, WL) at birth. Breast fed groups had significantly higher growth indices at 1 month (WA, LA), 2 months (WA) and 3 months (WA, LA) of age. Compared to breast fed groups, formula fed infants showed significantly higher WA z score changes in the 1-2, 2-3, 3-4, and 4-6 month intervals. LA z score changes were higher for breast fed infants at 0-1 month and for the formula fed infants at 4-6 months. In the 6-12 month interval growth indices progressively increased for the formula fed infants and declined for infants breast fed for longer (12 months). The 0-12 month changes in WA, LA, and WL z scores were positive for formula fed infants and negative for the 12 month breast fed group. Nevertheless, the 12 month breast fed group showed an absolute WA z score just below 0 (mean (SEM) -0.04 (0.26)) at 12 months. CONCLUSION: The growth pattern of breast fed and formula fed Italian infants differs in the first 12 months of life. This questions the validity of current reference values for monitoring the growth of breast fed infants. Growth indices in breast fed groups, high at birth and closer than expected to the reference at 12 months, may reflect differences in genetic factors, intrauterine conditions, or both.


Subject(s)
Bottle Feeding , Breast Feeding , Child Development , Growth , Body Height/physiology , Body Weight/physiology , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Male , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...